Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly (LLY) has recently underperformed, with shares declining 18.7% in the past month against the S&P 500's 5.2% gain, though revenue is expected to grow significantly with a 27.5% year-over-year increase for the current quarter and 32.9% for the current fiscal year. While earnings estimates have been revised slightly downward, the company anticipates a 41.3% increase in earnings per share for the current quarter and a 70.1% increase for the current fiscal year. Currently, Lilly holds a Zacks Rank #3, suggesting near-term performance in line with the broader market.

Analysis

Eli Lilly (LLY) has garnered significant investor focus despite a notable share price contraction of 18.7% over the past month, a stark contrast to the S&P 500 composite's 5.2% gain and underperforming the Zacks Large Cap Pharmaceuticals industry's 6.2% loss. Despite this recent market underperformance, the company's fundamental growth outlook remains robust. Consensus sales estimates project a 27.5% year-over-year (YoY) increase for the current quarter to $14.41 billion. For the current fiscal year, revenues are anticipated to reach $59.85 billion, a 32.9% YoY growth, with a further 21.3% increase to $72.59 billion forecasted for the next fiscal year. Earnings per share (EPS) are also on a strong upward trajectory, with the current quarter expected to deliver $5.54, a 41.3% YoY increase, and the current fiscal year's EPS estimated at $22.09, marking a 70.1% YoY surge. Next fiscal year's EPS is projected to grow by an additional 39.4%. However, it's pertinent to note that consensus earnings estimates have seen minor downward revisions over the last 30 days: -0.8% for the current quarter, -1.5% for the current fiscal year, and -1.2% for the next fiscal year. In its last reported quarter, Lilly's revenues of $12.73 billion (a 45.2% YoY increase) surpassed consensus by 0.86%, but its EPS of $3.34 missed Zacks Consensus Estimate by 5.11%. The company currently holds a Zacks Rank #3 (Hold), suggesting its near-term stock performance may align with the broader market, and its Zacks Value Style Score of C indicates it is trading at par with its peers.

Key Decisions for Investors

• Investors should assess whether the recent 18.7% pullback in LLY's share price presents a strategic entry point, balancing the strong multi-year revenue and earnings growth projections against the slight downward revisions in near-term consensus estimates and recent stock underperformance.
• It is advisable to closely monitor upcoming quarterly earnings reports for a return to EPS estimate beats, which could validate the ambitious growth narrative and potentially reverse negative sentiment stemming from the previous EPS miss.
• The Zacks Rank #3 (Hold) and Value Style Score of C (at par with peers) suggest a neutral near-term outlook; therefore, investors might consider a phased approach or await further catalysts before significantly altering positions, acknowledging that current valuation fairly reflects peer comparisons.